Pipeline — registered trials by phase
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
— · Hematologic Malignancy, Solid Malignancy · Enrolling By Invitation · est. 2038-08
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
— · Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders · Completed · est. 2023-01-19
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
— · SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis · Recruiting · est. 2031-12-31
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
— · Cardiovascular, Metabolic Disease, Dyslipidemias · Recruiting · est. 2027-06
A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
— · Hypertension · Recruiting · est. 2028-07-01
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
— · Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma · Completed · est. 2025-09-18
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
— · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy · Recruiting · est. 2030-01
A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)
— · Alpha-1 Antitrypsin Deficiency (AATD) · Not Yet Recruiting · est. 2030-06-30
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
— · Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease · Not Yet Recruiting · est. 2029-12-30
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
— · Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia · Recruiting · est. 2033-12
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
— · T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia · Completed · est. 2026-03-11
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where CRISPR Therapeutics is lead sponsor; 11 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- 10-Q2026-08-03Quarterly report
- 8-K2026-08-03Current report (material event)
- SCHEDULE 13G/A2026-07-27SCHEDULE 13G/A
- S-82026-06-05Employee stock plan
- 8-K2026-06-04Current report (material event)
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- SCHEDULE 13G2026-05-14SCHEDULE 13G
- 10-Q2026-05-04Quarterly report
- 8-K2026-05-04Current report (material event)
- SCHEDULE 13G/A2026-04-30SCHEDULE 13G/A
- ARS2026-04-21Annual report to holders
- DEFA14A2026-04-21DEFA14A
- DEF 14A2026-04-21Proxy statement
- PRE 14A2026-04-02PRE 14A
- 8-K2026-03-16Current report (material event)
- 8-K2026-03-11Current report (material event)
- SCHEDULE 13G/A2026-02-17SCHEDULE 13G/A
- 10-K2026-02-12Annual report
- 8-K2026-02-12Current report (material event)
- SCHEDULE 13G/A2026-02-05SCHEDULE 13G/A
- 8-K2026-01-12Current report (material event)
- SCHEDULE 13G2025-11-14SCHEDULE 13G
- 10-Q2025-11-10Quarterly report
- 8-K2025-11-10Current report (material event)
- SCHEDULE 13G/A2025-11-04SCHEDULE 13G/A
- 8-K2025-10-15Current report (material event)
- 424B52025-10-15Prospectus (offering)
- 10-Q2025-08-04Quarterly report
- 8-K2025-08-04Current report (material event)
- SCHEDULE 13G2025-07-17SCHEDULE 13G
- 8-K2025-06-26Current report (material event)
- 8-K2025-06-09Current report (material event)
- 424B52025-05-19Prospectus (offering)
- 8-K2025-05-19Current report (material event)
- SCHEDULE 13G/A2025-05-14SCHEDULE 13G/A
- SCHEDULE 13G/A2025-05-13SCHEDULE 13G/A
- 10-Q2025-05-06Quarterly report
- 8-K2025-05-06Current report (material event)
- ARS2025-04-16Annual report to holders
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.